We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Autoimmune activation and hypersensitization of the AT<sub>1</sub> and ET<sub>A</sub> receptors contributes to vascular injury in scleroderma renal crisis.
- Authors
Hegner, Björn; Kretzschmar, Tobias; Zhu, Nan; Kleinau, Gunnar; Zhao, Hongfan; Kamhieh-Milz, Julian; Hilger, Julia; Schindler, Ralf; Scheerer, Patrick; Riemekasten, Gabriela; Philippe, Aurélie; Catar, Rusan
- Abstract
Objectives Scleroderma renal crisis (SRC) is a rare vascular complication of systemic sclerosis with substantial risks for end-stage renal disease and premature death. Activating autoantibodies (Abs) targeting the angiotensin II type 1 (AT1R) and the endothelin-1 type A receptor (ETAR) have been identified as predictors for SRC. Here, we sought to determine their pathogenic significance for acute renal vascular injury potentially triggering kidney failure and malignant hypertension. Methods IgG from patients with SRC was studied for AT1R and ETAR dependent biologic effects on isolated rat renal interlobar arteries and vascular cells including contraction, signalling and mechanisms of receptor activation. Results In myography experiments, patient IgG exerted vasoconstriction sensitive to inhibition of AT1R and ETAR. This relied on MEK-ERK signalling indicating functional relevance of anti-AT1R and anti-ETAR Abs. The contractile response to angiotensin II and endothelin-1 was amplified by patient IgG containing anti-AT1R and anti-ETAR Abs with substantial crosstalk between both receptors implicating autoimmune receptor hypersensitization. Co-immunoprecipitation experiments indicated heterodimerization between both receptor types which may enable the observed functional interrelation by direct structural interactions. Conclusion We provide experimental evidence that agonistic Abs may contribute to SRC. This effect is presumably related to direct receptor stimulation and additional allosteric effects, at least in heterodimeric receptor constellations. Novel therapies targeted at autoimmune hyperactivation of AT1R and ETAR might improve outcomes in severe cases of SRC.
- Subjects
AUTOANTIBODIES; BIOMARKERS; MALIGNANT hypertension; IMMUNOGLOBULINS; ENDOTHELINS; MUSCLES; SYSTEMIC scleroderma; CELL receptors; PRECIPITIN tests; RISK assessment; DIAGNOSIS; RESEARCH funding; VASCULAR diseases; VASOCONSTRICTION; ACUTE kidney failure
- Publication
Rheumatology, 2023, Vol 62, Issue 6, p2284
- ISSN
1462-0324
- Publication type
Article
- DOI
10.1093/rheumatology/keac594